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A. Lowery1 and S. Sultan1*1Department of Vascular and Endovascular Surgery, Western Vascular Institute, University College Hospital,
Galway, Ireland;
2Department of Vascular and Endovascular Surgery, Galway Clinic, Doughiska, Dublin Road, Galway, IrelandBackground. Plasma Haemoglobin A1c (HbA1c) reflects ambient mean glycaemia over a 2–3 months period. Reports
indicate that patients, with and without diabetes, with an elevated HbA1c have an increased risk of adverse outcome
following surgical intervention. Our aim was to determine whether elevated plasma HbA1c level was associated with
increased postoperative morbidity and mortality in patients undergoing vascular surgical procedures.
Methods. Plasma HbA1c was measured prospectively in 165 consecutive patients undergoing emergency and elective
vascular surgical procedures over a 6-month period. Patients were categorized into four groups depending on whether their
plasma HbA1c was%6%, 6.1–7%, 7.1–8% orO8% and clinical data was entered into a prospectively maintained database.
Patients were also classified by diabetic status with suboptimal HbA1c in a patient without diabetes beingO6 to%7% and
suboptimal HbA1c in a patient with diabetes beingO7%. Patients with plasma HbA1cO7% were reclassified as having
undiagnosed diabetes mellitus. Composite primary endpoints were all cause 30-day morbidity and mortality and all cause 6-
month mortality. Composite secondary endpoints were procedure specific complications, adverse cardiac events, stroke,
infection and mean length of hospital stay.
Results. Of the 165 patients studied, 43 (26.1%) had diabetes and the remaining 122 (73.9%) did not. The mean age was 72
years and 59% were male. Suboptimal HbA1c levels were found in 58% patients without diabetes and in 51% patients with
diabetes. In patients without diabetes those with suboptimal HbA1c levels (6–7%) had a significantly higher incidence of
overall 30-day morbidity compared to patients with HbA1c levels%6% (56.5 vs 15.7%, p!0.001). Similarly, for patients
with diabetes those with suboptimal HbA1c levels (HbA1cO7%) had a significantly higher incidence of 30-day morbidity
compared to those with HbA1c levels %7% (59.1% vs 19%, pZ0.018). Multivariate analysis revealed that a plasma
HbA1c level ofO6 to%7% was a significant independent predictor of overall 30-day morbidity in patients without diabetes
undergoing vascular surgical procedures. No difference in mortality, composite secondary endpoints, procedure specific
complications, stroke or mean length of hospital stay was observed between any of the groups in the study.
Conclusion. Suboptimal HbA1c levels may hold prognostic significance in patients without diabetes undergoing vascular
surgery.Keywords: Haemoglobin A1c; HbA1C; Risk factors; Vascular surgery; Postoperative; Morbidity; Diabetes mellitus.Introduction
Plasma haemoglobin A1c (HbA1c) reflects mean
ambient fasting and postprandial glycaemia over a
2–3 months period. HbA1c is formed by the slow
irreversible, non-enzymatic glycation of valine and
lysine residues in the haemoglobin molecule.1 It is aing author. S. Sultan, Consultant Vascular and Endo-
geon, Department of Vascular and Endovascular
tern Vascular Institute, University College Hospital,
nd.
: sherifsultan@esatclear.ie
0188+ 10 $35.00/0 q 2006 Elsevier Ltd. All rights reseruseful test for characterising dysglycemia as it is easier
to perform than an oral glucose tolerance test and is
independent of patient prandial status.2,3
Elevated HbA1c levels (O7%) are associated with a
higher incidence of microvascular and macrovascular
complications in patients with type 1 and type 2
diabetes mellitus. It has been shown conclusively that
a reduction in plasma HbA1c levels below 7%, leads to
a lower incidence of microvascular complications in
both type 1 and type 2 diabetes mellitus.4,5 However,
the corollary that a reduction in plasma HbA1c levels
would lead to a similar reduction in the incidence ofEur J Vasc Endovasc Surg 32, 188–197 (2006)
doi:10.1016/j.ejvs.2006.01.011, available online at http://www.sciencedirect.com onved.
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failed to reach clinical statistical significance.4,5
Currently much attention has been focused on the
role of HbA1c in characterising dysglycaemia in
patients without diabetes.2,6–12 Recent studies have
indicated that patients (both without and without
diabetes) with an elevated HbA1c have a higher rate of
adverse outcomes following cardiac surgery and
percutaneous coronary intervention.6,7,13 Other
studies have implicated HbA1c as an independent
risk factor for cardiovascular events and the develop-
ment of atherosclerosis, independent of diabetes
status.9,14
To our knowledge, there have been no previous
studies examining plasma HbA1c levels and outcomes
in vascular patients. In this study, we sought to
characterise whether a patient’s preoperative glycae-
mia, as reflected by plasmaHbA1c, was related to peri-
operative morbidity, mortality and average length of
hospital stay in both non-diabetic and patients with
diabetes undergoing vascular surgical procedures.Methods
Preoperative plasma HbA1c levels were prospectively
collected from all patients admitted for a vascular
surgery procedure over a 6-month period. Patients
admitted for both emergency and elective procedures
were included in the study. Those with a history of a
recent blood transfusion or a haemoglobinopathy
were excluded from the study, as plasma HbA1c
measurements in these patients are known to be
unreliable.15 Clinical data was collected and entered
into a prospectively maintained database (Vascubasew,
Consensus Medical, USA).
The clinical data included in the study were: plasma
HbA1c level, risk factors for vascular disease and co-
morbidities (diabetes mellitus, hypertension, smoking,
dyslipidaemia, cardiac risk factors [i.e. previous
myocardial infarction, angina pectoris, congestive
heart failure, preexisting arrhythmia]), preoperative
fasting plasma glucose levels, length of hospital stay
(LOS), postoperative morbidity and mortality. The
local ethical review board were consulted about this
study.
Emergency procedures were included in this study
so to avoid selection bias. Samples for plasma HbA1c
were collected preoperatively from all patients
admitted for acute procedures along with the other
routine preoperative bloods. However, fasting blood
samples (e.g. for glucose, lipids etc.) were done within
1 week postoperatively in all patients admitted for
emergency procedures.Patients were stratified into four groups based on
their plasma HbA1c level: group 1ZHbA1c%6%,
group2ZHbA1c 6.1–7.0%, group 3ZHbA1c 7.1–8.0%
and group 4ZHbA1c O8%. Patients were further
classified as either having or not having diabetes.
Patients without diabetes were defined as those
without a history of diet or pharmacologically
controlled diabetes mellitus, a plasma HbA1c level
%7% and a preoperative fasting plasma glucose !
7.0 mmol/l.6 Patients with diabetes were defined as
those with a history of either type 1 or type 2 diabetes
mellitus as given in the medical history on admission,
and/or those taking either insulin and/or oral
hypoglycaemic agents or two consecutive preopera-
tive fasting plasma glucose levels R7.0 mmol/l. For
patients without diabetes, a plasma HbA1c O6 and
%7% was considered suboptimal.6,15 In contrast, for
patients with diabetes, a plasma HbA1c O7% was
considered suboptimal.16 HbA1c levels were
measured using high pressure liquid chromatography
(HPLC), coefficient of variation!1%.
All patients with diabetes were reviewed by a
consultant endocrinologist both preoperatively and
postoperatively. Preoperatively, patients with diabetes
were put on an insulin/dextrose infusion and insulin
sliding scale if clinically indicated. Blood sugars were
measured routinely by nursing staff using a gluc-
ometer and the appropriate dose of insulin was given
according to the sliding scale.
Postoperatively, capillary blood glucose levels were
monitored 2–4 times daily on all patients with diabetes
by nursing staff using a glucometer. These blood sugar
levels were monitored daily by a consultant endocri-
nologist or by a member of the endocrinology team
and the appropriate measure (e.g. diet, oral hypogly-
caemic, insulin, sliding scale) was implemented to try
and maintain blood sugar in the range 4–6 mmol/l.
Those newly diagnosed with diabetes were referred
to the endocrinology service for a comprehensive
assessment.Endpoints
The composite primary endpoints for the study were
all cause 30-day morbidity and mortality and all cause
6-month mortality. The composite secondary end-
points were procedure specific complications, stroke,
adverse cardiac events (cardiac arrest, myocardial
infarction, pulmonary oedema), infection and mean
length of hospital stay. Adverse cardiac events were
detected by postoperative monitoring of patients
for clinical symptoms of chest pain, palpitations and
shortness of breath or unresponsiveness. Serial 12-leadEur J Vasc Endovasc Surg Vol 32, August 2006
Table 1. Baseline characteristics (all patients nZ165)
A1c%6% A1c 6.1–7% A1c 7.1–8% A1cO8% Total p-value
Number 56 78 18 13 165 ns
Age (yrs) 72G9 72G7 72G5 70G7 72G8 ns
Male 57.1% 57.7% 55.6% 76.9% 58.8% ns
Hypertension 69.6% 67.9% 83.3% 69.2% 70.3% ns
Smoking 62.5% 61.5% 61.1% 46.2% 60.6% ns
Dyslipidaemia* 42.9% 64.1% 66.7% 76.9% 58.2% ns
Renal impairment† 17.9% 9% 33.3% 30.8% 16.4% ns
Cardiac risk factors‡ 48.2% 42.3% 61.1% 30.8% 45.5% ns
HbA1c (%) 5.7G0.3 6.5G0.3 7.5G0.3 10.2G2.5 6.6G1.4 !0.001
Mean FPG (mmol/l) 5.3G0.5 5.6G0.8 7.1G1.2 9.4G2.7 6.0G1.6 !0.001
Statin (% on admission) 16.1 21.8 22.2 23.1 20 ns
Beta-blocker (% on
admission)
14.3 10.3 16.7 38.5 14.5 ns
FPG, fasting plasma glucose.
* Reported history of dyslipidaemia or treatment with a lipid lowering agent.
† Preoperative plasma creatinineR133 mmol/L (1.5mg/dL).
‡ Previous myocardial infarction, angina pectoris, congestive heart failure, preexisting arrhythmia.
C. J. O’Sullivan et al.190electrocardiograms, cardiac enzymes and troponins
were performed on all postoperative patients, regard-
less of symptoms. A clinical history of shortness of
breath and/or orthopnoea and/or paroxysmal noc-
turnal dyspnoea with suggestive chest X-ray changes
was used to diagnose pulmonary oedema. All patients
were followed up 6 months after the study period to
assess endpoints.Table 2. Interventions
n %
All procedures 165 100Statistical analysis
All data were analysed using SPSSw Version 12.0.1.
Continuous variables were analysed by two groups
only using 2-tailed t-testing and between more than
two groups by using ANOVA followed by posthoc
testing with Tukey HSD. Categorical variables were
analyzed with the chi-square or Fisher exact test,
where appropriate. All baseline characteristics, risk
factors and co-morbidities were analyzed to determine
the univariate predictors of overall 30-day post-
operative morbidity. All univariate variables with a
p-value of!0.25 were entered into a stepwise multiple
logistic regression analysis. Age and sex were
included regardless of the p-value. A p-value of !
0.05 was assumed to represent statistical significance.Carotid procedures 54 32.8
Carotid endarterectomy 43 26.1
Carotid artery stenting technique 11 6.7
Aorta procedures 36 21.8
Open abdominal aortic aneurysm repair 18 10.9
Endovascular aortic aneurysm repair 18 10.9
Peripheral artery procedures 59 35.8
Peripheral artery angioplasty 30 18.2
Peripheral artery bypass 26 15.8
Arterial embolectomy 3 1.8
Amputation procedures 16 9.6
Major (AKA, BKA) 3 1.8
Minor (TMA, toe amputation) 13 7.8Results
From July 2004 to December 2004, 165 patients (97
males and 68 females) were admitted for emergency
and elective vascular surgical procedures. No patients
met the exclusion criteria. Of the 165 patients, 122
(73.9%) were non-diabetic and 43 (26.1%) were
diabetic. Ten patients had type 1 diabetes mellitusEur J Vasc Endovasc Surg Vol 32, August 2006and 33 patients had type 2 diabetes mellitus. The mean
age was 72 years with the range being 48–88 years.
Suboptimal HbA1c levels were found in 71 (58.2%)
patients without diabetes and in 22 (51.2%) patients
with diabetes. The overall mean length of hospital stay
was 20.9 days (standard deviation [SD] 21.6). A total of
62 out of 165 patients (37.6%) suffered either an intra-
operative or a postoperative complication within 30-
days, one patient died within 30 days (0.6%) and nine
patients (5.5%) died within 6 months. Plasma HbA1c
levels were obtained an average of 5.5 days (range 0–
16 days) prior to the procedure.
Baseline characteristics for all patients in the study
are given in Table 1 and Table 2 shows the procedures
performed.Plasma HbA1c group distribution
Plasma HbA1c distribution among the different
groups is shown in Fig. 1. Among patients without
diabetes, 62 (50.8%) patients had suboptimal (HbA1c
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Fig. 1. Haemoglobin A1c (HbA1c) group distribution for all
patients, diabetics and non-diabetics.
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51 (41.8%) patients had optimal preoperative plasma
HbA1c level (HbA1c%6%). Nine patients (7.4%) who
were originally categorized as not having diabetes
mellitus had a plasma HbA1c O7%. These patients
were subsequently reclassified as having undiagnosed
diabetes mellitus, fasting plasma glucose levels
confirmed their status. Among the patients with
diabetes, 21 patients (48.8%) had optimal preoperative
plasma HbA1c levels (HbA1c %7%) and 22 patients
(51.2%) had suboptimal plasma HbA1c levels (HbA1c
O7%).Composite primary endpoints
The all-cause 30-day morbidity rate for groups 1–4 is
shown in Fig. 2. Among patients without diabetes,
those with HbA1c levels of 6.1–7% had a significantly
higher incidence of all-cause 30-day morbidity
compared to patients with HbA1c levels %6% (56.5%All-Cause 30-day
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Fig. 2. All-cause 30-day postoperative morbidity rate for all pavs 15.7%, 95% CI Z2.8–17.2, RR 7.0, p!0.001).
Similarly among patients with diabetes, patients with
HbA1c levels O7% also had a significantly higher
incidence of all-cause 30-day morbidity compared to
patients with HbA1c levels %7% (59.1% vs 19%, 95%
CI 1.5–24.4, RR 6.1, pZ0.018).
No significant differences in 30-day or 6 month
mortality were observed among any of the groups.Comparison of patients with and without diabetes
Comparisons of 30-day morbidity rates for patients
with and without diabetes are shown in Fig. 5. There
was no significant difference between patients without
diabetes with plasma HbA1c levels between 6.1 and
7% and patients with diabetes mellitus (56.5% vs
39.5%, pZ0.1). However, a significant difference was
observed between patients without diabetes with
plasma HbA1c levels%6% and patients with diabetes
mellitus (15.7% vs 39.5%, 95% CI 1.3–9.3, RR 3.5, pZ
0.018). These results would appear to suggest that an
adverse outcome is more dependent on the preopera-
tive plasma HbA1c level than on the diabetes status of
the patient.Comparison of types I and II diabetes mellitus
No significant differences in all cause 30-day morbid-
ity (30% vs 42.4%, pZ0.7), 6-month mortality (10% vs
3%, pZ0.9) or length of hospital stay (22.7 days vs
25.03 days, pZ0.7) were observed between patients Morbidity Distribution
7.1 – 8.0% >8%
bA1c (%)
ALL
NDM
DM
betics
.018
tients, patients without diabetes and patients with diabetes.
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Fig. 3. All-cause 30-day postoperative morbidity rate for all
procedures and each individual procedure among patients
without diabetes only. (A, all procedures; B, carotid
procedures; C, aortic procedures; D, peripheral arterial
procedures; E, amputation procedures). ns, non-significant.
C. J. O’Sullivan et al.192with type 1 (nZ10) and type 2 (nZ33) diabetes
mellitus.Composite secondary endpoints
There was a significantly higher incidence of adverse
cardiac events among patients without diabetes with
preoperative plasmaHbA1c levels between 6.1 and 7%
undergoing aortic procedures (35% vs 0%, pZ0.012).
There was also an overall higher incidence of post-
operative infection (21.1% vs 5.9%, pZ0.037), particu-
larly postoperative wound infection (9.9% vs 0%, p!
0.05) among patients without diabetes with preopera-
tive plasma HbA1c levels between 6.1 and 7%.
No significant differences in the other secondary
endpoints of procedure specific complications, stroke,
or mean length of hospital stay (Fig. 4) were observed
between the groups.56 .5
60.0
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P=0. 018
All-cause 30-day
morbidityProcedure specific endpoints
The all-cause 30-day morbidity rate for all procedures
and each individual procedure (i.e. carotid, aortic,Length of Stay
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Fig. 4. Mean length of hospital stay for all patients, patients
without diabetes and patients with diabetes. ns, non-
significant.
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without diabetes is shown in Fig. 3. Patients without
diabetes who underwent peripheral arterial surgery
and aortic surgery with a preoperative plasma HbA1c
6.1–7% had a significantly higher all-cause 30-day
postoperative morbidity than patients with a pre-
operative plasma HbA1c%6% (aortic surgery: 50% vs
6.7%, RR 14.0, 95% CI 1.5–130, pZ0.009, peripheral
arterial surgery: 77.8% vs 20%, RR 14, 95% CI 2.6–75.4,
pZ0.004). No significant differences in all-cause 30-
day morbidity were observed in the carotid artery and
amputation procedure subgroups (Fig. 5).
A total of 36 patients underwent aortic procedures
in this study. The aortic procedures comprised 18
patients in the EVAR group and 18 patients in the open
AAA group. Only one patient 1/36 had diabetes (type
II) with an optimal HbA1c level (HbA1cZ6.4%).
A total of 19/36 patients in the aortic procedure
group had suboptimal HbA1c levels. Nine of the
nineteen underwent an EVAR procedure and 10/19
underwent an open AAA repair. When these two
groups were compared, there was no significant
difference in overall 30-day morbidity (55.6% (EVAR)
vs 50%, pZ1.0) or 6-month mortality (11.1% vs 10%,
pZ1.0) (Table 5).
When peripheral arterial bypass was compared to
peripheral artery angioplasty and arterial embolect-
omy there was no significance difference in overall 30-
day morbidity (for those without diabetes, pZ0.9, for
those with diabetes, pZ0.3), 6-month mortality
(without diabetes, pZ1.0, with diabetes, pZ0.9) or
length of hospital stay (without diabetes, pZ0.06, with
diabetes, pZ0.07). When carotid endarterectomy was
compared with carotid artery stenting technique there
was no significant difference in overall 30-day
mortality (without diabetes, pZ0.9, with diabetes,15.7
39 .5
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Fig. 5. Comparisons of all-cause 30-day postoperative
morbidity between non-diabetic and patients with diabetes.
Table 3. Logistic regression: all patients
Variable OR 95% CI p-value
HbA1c
%6% 1.3 0.74–23.3 0.85
6.1–7.0% 5.8 2.37–14.2 !0.001*
7.1–8.0% 2.0 0.49–8.41 0.33
O8% 98.74 11.25–866.79 !0.001*
Hypertension 1.2 0.53–2.73 0.66
Smoking 0.87 0.39–1.93 0.73
Dyslipidaemia 0.74 0.34–1.59 0.44
Renal impairment 1.84 0.63–5.37 1.8
Diabetes mellitus 0.26 0.08–0.83 0.02*
Cardiac risk factors 1.0 0.46–2.19 0.98
Age (yrs) 1.0 0.96–1.06 0.79
Sex (male) 1.34 0.61–2.96 0.47
* Level of significance, p!0.05.
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length of hospital stay. When major amputations were
compared to minor amputations there was also no
significant difference in overall 30-day mortality, 6
month mortality or length of hospital stay.Predictors of postoperative morbidity
Univariate and multivariate analyses for all patients
and patients without diabetes, respectively, are shown
in Tables 3 and 4, respectively. Univariate analysis was
performed with 30-day morbidity as the dependent
variable and risk factors for adverse outcome,
including plasma HbA1c as the independent vari-
ables. Univariate predictors of adverse outcome
among all patients were plasma HbA1c 6.1–7%,
plasma HbA1c O8% and diabetes mellitus. Plasma
HbA1c O6 and %7% was the only univariate
predictor of 30-day morbidity to reach statistical
significance among patients without diabetes.
Surprisingly, among patients with diabetes, no
univariate predictors of 30-day postoperative morbid-
ity were identified.Table 4. Logistic regression: patients without diabetes
Variable OR 95% CI p-value
HbA1c
%6% 0.3 0.2–0.7 0.9
6.1–7.0% 10.86 3.76–31.41 !0.001*
7.1–8.0% 1.47 0.23–9.38 0.69
8% N/A N/A N/A
Hypertension 1.36 0.50–3.40 0.54
Smoking 0.58 0.23–1.50 0.26
Dyslipidaemia 0.64 0.25–1.64 0.35
Renal impairment 3.02 0.80–11.39 0.1
Cardiac risk factors 1.3 0.51–3.33 0.59
Age (yrs) 1.02 0.96–1.08 0.50
Sex (male) 1.03 0.41–2.6 0.1
* Level of significance, p!0.05.Discussion
This prospective cohort study, which included 122
patients without diabetes and 43 patients with
diabetes, set out to determine whether or not patients
with and without diabetes with suboptimal HbA1c
levels had a worse postoperative outcome than those
patients with optimal HbA1c levels in a vascular
surgical population. We found that both non-diabetic
and patients with diabetes with suboptimal HbA1c
levels had significantly higher 30-day postoperative
morbidity rates than non-diabetic and patients with
diabetes with optimal plasma HbA1c levels. Among
patients without diabetes, a plasma HbA1c O6 and
%7% was found to be a significant independent
predictor of overall 30-day postoperative morbidity.
Therefore, a suboptimal HbA1c level may hold
prognostic significance in patients without diabetes
undergoing vascular surgery.
It is has been suggested that diabetes mellitus
represents just ‘the measured tip of a much larger
‘dysglycemic iceberg’’.9 Raised glucose levels in the
circulation may speed up the process of atherosclero-
sis through putative mechanisms such as oxidative
stress and protein glycation of vessel walls.17 In
patients with diabetes, reducing plasma HbA1c levels
by tight glycaemic control lowers the risk of sub-
sequent microvascular disease. However, the relation
of reduced HbA1c levels with macrovascular out-
comes (e.g. stroke, ischaemic heart disease, peripheral
vascular disease) is less clear.5 Studies have concluded
that a progressive relation between glucose concen-
trations and cardiovascular disease extends below the
current threshold used to define diabetes mellitus.10,18
Therefore, patients without diabetes with suboptimal
HbA1c levels may have a level of dysglycaemia that
may not meet the criteria for a diagnosis of diabetes
mellitus, but may still contribute to an adverse
postoperative outcome. Plasma HbA1c would be a
more useful test for trying to identify these patients
preoperatively than other tests, such as fasting plasma
glucose level or an oral glucose tolerance test).3
Although some studies have shown an association
between abnormalities in fasting glucose below the
diabetes threshold and poor cardiovascular out-
come,19–21 in general there is a lack of conclusive
data relating fasting hyperglycaemia to cardiovascular
risk.22,23 Furthermore, other studies have indicated
that postprandial hyperglycemia may have more
prognostic significance in terms of cardiovascular
outcome compared with fasting hyperglycemia.24–26
However, diagnostic testing of postprandial plasma
glucose levels is cumbersome. HbA1c levels, on the
other hand, provide a simple, single-sampleEur J Vasc Endovasc Surg Vol 32, August 2006
Table 5. 30-day morbidity
30-day morbidity Non-diabetic
HbA1C!6%
Non-diabetic
HbA1CR6%
p Diabetic
HbA1C!7%
Diabetic HbA1C
R7%
p
NZ 51 71 21 22
Cardiac
Cardiac arrest 3 (4.2%) 0.264 1 (4.8%) 0.488
Myocardial infarction
NSTEMI 3 (4.2%) 0.264 1 (4.5%) 1
Ischaemic ECG changes 1 (2%) 0.418
Atrial fibrillation 4 (5.6%) 0.139 1 (4.5%) 1
Pulmonary oedema 5 (7%) 0.074 2 (9%) 0.488
Congestive cardiac failure 1 (1.4%) 1
Respiratory
Lower respiratory tract
infection
2 (4%) 6 (8.5%) 0.466 1 (4.5%) 1
Pleural effusion 5 (7%) 0.074 1 (4.5%) 1
Atelectasis 3 (4.2%) 0.264
Respiratory failure 3 (4.2%) 0.264 1 (4.5%) 1
Tracheostomy 1 (2%) 1 (1.4%) 1
Laryngeal oedema 1 (1.4%) 1
Renal
Acute renal failure 3 (4.2%) 0.264 1 (4.5%) 1
Renal impairment 1 (1.4%) 1
Cerebrovascular
Stroke 1 (1.4%) 1
TIA 1 (1.4%) 1
Limb loss
Above knee amputation 3 (6%) 5 (7%) 1 1 (4.5%) 1
Below knee amputation 1 (1.4%) 1 1 (4.5%) 1
Sepsis 1 (1.4%) 1 1 (4.5%) 1
MODS 1 (4.5%) 1
Miscellaneous
Rhabdomyolysis 1 (1.4%) 1
Haematoma
Neck 1 (2%) 3 (4.2%) 0.639
Groin 1 (2%) 3 (4.2%) 0.639 1 (4.5%) 1
Wound infection 7 (9.9%) 0.041* 1 (4.8%) 5 (22.7%) 0.185
Wound seroma 1 (4.8%) 0.488
Graft complications
Graft infection 1 (2%) 1 (1.4%) 1
Graft occlusion 2 (2.8%) 0.509
Graft perforation 1 (1.4%) 1
Acute limb ischaemia 2 (2.8%) 0.509
* Level of significance, p!0.05.
C. J. O’Sullivan et al.194determination, that is reflective of both fasting and
postprandial glycaemia.
We did not perform an oral glucose tolerance test
(OGTT) on any of the patients included in our study as
it was deemed too time consuming and involved the
patients receiving two episodes of phlebotomy (one
preprandial and one 2 h postload glucose) instead of
just one. We, therefore, only collected blood samples
for HbA1C and we collected fasting plasma glucose
levels from each of the patients as outlined in the
methods section in the paper. An advantage of HbA1C
levels was that they gave an indication of chronic
hyperglycaemia. The average time-period plasma
HbA1c levels were taken prior to surgery among the
165 patients included in the study was 5.47 days
(standard deviation 4.45). A long time period between
testing and surgery was arbitrarily chosen asO5 daysEur J Vasc Endovasc Surg Vol 32, August 2006and %16 days. There was no significant difference in
the predictive value in those with a long time period
between testing and surgery (i.e. O5 days and
%16 days) and those with a short time period between
testing and surgery (i.e. %5 days). When univariate
analysis was performed in all patients who had
plasma HbA1c levels measured %5 days prior to
surgery, a plasma HbA1c level O6 and %7% was a
significant independent predictor of overall 30-day
postoperative morbidity (odds ratio (OR) 4.8, 95%
confidence interval (CI) 1.4–16.8, pZ0.015) as was a
plasma HbA1c O8% (OR 80.1, 95% CI 6.9–921.0, p!
0.001). When univariate analysis was performed in all
patients who had plasma HbA1c levels measuredO5
and%16 days prior to surgery (i.e. a long time period
between testing and surgery, plasma HbA1c levelO6
and %7% remained a significant independent
Haemoglobin A1c (HbA1C) in Non-diabetic and Diabetic Vascular Patients 195predictor of 30-day postoperative morbidity (OR 4.6,
95% CI 1.3–17, pZ0.021). When univariate analysis
was performed in patients without diabetes alone who
had plasma HbA1c levels done %5 days prior to
surgery, a plasma HbA1c O6 and %7% was a
significant independent predictor of 30-day post-
operative morbidity (OR 16.9, 95% CI 2.6–110, pZ
0.003). When univariate analysis was performed in
patients without diabetes who had plasma HbA1c
levels done O5 and %16 days prior to surgery, a
plasma HbA1c O6 and %7% remained a significant
independent predictor of overall 30-day postoperative
morbidity (OR 9.8, 95% CI 2.1–46. 8, pZ0.004). Among
non-diabetics with suboptimal HbA1c levels (HbA1c
6–7%) 17.7% had impaired fasting glucose, as defined
by the American Diabetes Association (ADA).13 In
comparison, 13.7% of non-diabetics with optimal
HbAlc levels (HbA1c%6%) had impaired glucose
tolerance (as defined by the American Diabetic
Association). There was no significant difference
between these two groups (pZ0.7) impaired fasting
glucose was not predictive of an adverse outcome.
However, we did find that suboptimal HbA1c levels
were associated with an adverse postoperative
outcome.
In our study, over half of the patients without
diabetes (50.8%) presenting for vascular surgical
procedures had chronic hyperglycaemia as reflected
by suboptimal plasma HbA1c levels. Similarly, over
half of the patients with diabetes (51.2%) presenting
for vascular surgical procedures had suboptimal
HbA1c levels (HbA1c O7%) as defined by the ADA.
In a study on HbA1C levels in patients without
diabetes under going percutaneous coronary revascu-
larisation, Corpus et al.6 found that the incidence of an
abnormal haemoglobin A1c level (i.e. O6%) was
approximately 32%. This was explained by many of
the characteristics of the insulin-resistant state such as
obesity, dyslipidemia, and hypertension, which also
are risk factors for atherosclerosis. They also postu-
lated that the first clinical manifestation of this
‘prediabetic state’ is coronary artery disease. In
addition Lauruschkat et al.,27 in a study of 7310
patients undergoing coronary artery bypass grafting
found that those with undiagnosed diabetes had the
poorest outcome. The authors concluded that the
presence of more cardiac-type risk factors than
peripheral arterial vascular risk factors suggested a
briefer duration of the disease, which might in turn
explain the occult diagnosis. This was made all the
more likely by the fact that type 2 diabetes is often
diagnosed with a delay of as much as 7 years after the
actual onset of the disease. This may well explain whyHbA1C levels in our study of vascular patients were
greater than those in cardiac studies.
We found no significant difference in 30-day post-
operative morbidity between patients with and with-
out diabetes. When patients without diabetes with
suboptimal HbA1c levels (HbA1c 6–7%) were
compared with patients with diabetes there was no
significant difference in postoperative morbidity.
However, there was a significant difference in 30-day
postoperative morbidity between patients without
diabetes with optimal HbA1c levels (HbA1c %6%)
and patients with diabetes. Hence, the diabetes status
of the patient may be less important in determining
postoperative outcome than the preoperative plasma
HbA1c level (similarly the diagnosis of dyslipidaemia
is less important than the actual fasting plasma low-
density lipoprotein cholesterol level in determining
cardiovascular risk).9
A previous study by Khaw et al.2 demonstrated that
a raised HbA1c predicted mortality and cardiovas-
cular disease in patients without diabetes in the
community. They found that an increase in HbA1c of
1% was associated with a 20–30% increase in mortality
or cardiovascular events.2 It was thought that HbA1c
resembles blood pressure or cholesterol in terms of the
continuous relation with cardiovascular risk. How-
ever, in our study, although patients with suboptimal
HbA1c levels did have a higher mortality rate than
those with optimal HbA1c levels, the differences were
not statistically significant. The reasons for this are
unclear. It may be due to the fact that all of our patients
are treated aggressively preoperatively by high-dose
(80 mg) atorvastatin, with a cardio-selective beta-
blocker and aspirin. For patients with ischaemic
heart disease we add amlodipine. All patients are
commenced on clopidegrol postoperatively.28 As the
mortality rate in our study was overall relatively low
(5.5%), larger studies over a longer time period may be
required to find any appreciable significant difference
in mortality rates. Previous studies on cardiac patients
undergoing coronary bypass grafting have reported a
rise in hospital mortality rates of patients with
diabetes and of previously undiagnosed patients
with diabetes.29,30 Remarkably, the highest mortality
rate was found among the group of patients with
undiagnosed diabetes.
Previous major studies, comparing bypass surgery
with interventional cardiology (PTCA/stenting), have
reported that in the 5-year survival, there were no
significant differences between these therapy strat-
egies.31 However, in the bypass angioplasty revascu-
larization investigation (BARI) the infarction mortality
rate in the subgroup of patients with diabetes mellitus
assigned to the coronary surgery group wasEur J Vasc Endovasc Surg Vol 32, August 2006
C. J. O’Sullivan et al.196significantly lower than that in the PTCA group.32
Later studies33–35 confirmed that coronary surgery
leads to significantly better results in patients with
diabetes. However, in all these studies the ‘diabetes
mellitus’ status was acquired only under categorical
terms. Patients were deemed as having diabetes
according to the admission diagnosis based on
information given by the patient and documented
use of oral anti-diabetic agents or insulin therapy.
Hence, inclusion of those with occult diabetes in the
group without diabetes could have biased results. We
found no significant difference between open and
endovascular procedure results.
In conclusion, we found that the half of patients
without diabetes presenting for vascular surgery had
chronic hyperglycaemia, as determined by plasma
HbA1c O6 and %7%,. Similarly half of the patients
with diabetes presenting for vascular surgery had
suboptimal HbA1c levels (HbA1cO7%). Both patients
with and without diabetes with suboptimal HbA1c
levels had a higher incidence of 30-day postoperative
morbidity compared to those with optimal HbA1c
levels. Multivariate analysis revealed that in patients
without diabetes, a plasmaHbA1cO6 and%7%was a
significant independent predictor of overall 30-day
morbidity. A suboptimal HbA1c level, therefore, may
have prognostic significance in patients without
diabetes undergoing vascular surgery.References
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